Ultragenyx Pharma (RARE) Tops Q1 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Ultragenyx Pharma (RARE) Tops Q1 EPS by 8c

Ultragenyx Reports First Quarter 2017 Financial Results and Corporate Update

May 4, 2017 4:05 PM EDT

NOVATO, Calif, May 04, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the quarter ended March 31, 2017.

We have started the year with positive data from our pediatric and adult studies of burosumab and look forward to moving this key program through the regulatory process in both the US and Europe this year, said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. We believe the... More